Mentor Capital Cancer Immunotherapy Index Gains 29% During First Half of 2012
7/23/2012 10:26:49 AM
SAN DIEGO--(BUSINESS WIRE)--Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index has appreciated 28.7% during the first half of 2012. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the first half the biotech indices averaged a 30.7% gain. In comparison, during the first six months of 2012, the Dow, S&P 500 and NASDAQ Composite indices appreciated 5.42%, 8.31% and 12.66%, respectively.